Generic IUD Avibela Launches to Expand Contraceptive Choice in South Africa

CAPE TOWN, South Africa – April 22, 2026 – A significant new option in women's reproductive health has arrived in South Africa with the launch of Avibela®, the country's first generic hormonal intrauterine device (IUD). The announcement, made by women’s health organization Medicines360 and leading generics company Pharma Dynamics, marks a pivotal effort to expand access to long-acting reversible contraception (LARC) and treatment for heavy menstrual bleeding (HMB).

With an estimated 64% of pregnancies in South Africa being unplanned, the introduction of a more affordable, long-term contraceptive method is being hailed as a critical public health development. Avibela, a levonorgestrel 52 mg IUD, is more than 99% effective at preventing pregnancy and is approved for up to six years of use in the country.

“Building access strategies alongside innovation from the start is essential to closing the decades‑long gap between scientific discovery and real‑world delivery,” said Kelly Dannucci, Senior Director, Global Access at Medicines360. “Our partnership with Pharma Dynamics represents an important step forward in expanding access to our cost‑effective, clinically proven hormonal IUD, giving women in South Africa more choices in their contraceptive and menstrual health care.”

A Public Health Imperative

South Africa has a long-running family planning program, and an estimated nine million women currently use modern contraceptive methods. However, the landscape is overwhelmingly dominated by short-acting methods like contraceptive pills, injectables, and condoms. Long-acting methods, particularly IUDs, have struggled to gain a foothold, representing a mere 1.9% of the national contraceptive mix.

This low uptake persists despite the clear benefits of LARCs, which offer highly effective, long-term pregnancy protection without the need for daily adherence. The reliance on shorter-term methods contributes to the high rate of unintended pregnancies, placing a strain on both individual women and the public health system. Avibela's introduction directly targets this gap, offering a “set and forget” option that provides continuous protection for over half a decade.

Dismantling Long-Standing Barriers

The underutilization of IUDs in South Africa is rooted in a complex web of barriers that Avibela’s launch aims to unravel. The most significant of these has been the high upfront cost. In the private sector, branded hormonal IUDs like Mirena® can cost between R4,000 and R5,000 for the device alone, with insertion fees adding several thousand more. This price point places them far out of reach for the majority of women.

“While IUDs are among the most cost‑effective methods over time, the initial expense has placed them out of reach for many women,” said Ingrid Singels, Associate Director of the Scientific Division at Pharma Dynamics. “By introducing an affordable, clinically equivalent generic IUD, we’re helping remove a long‑standing barrier to access -- so more women can consider the hormonal IUD for contraception and/or treatment of HMB.”

Beyond cost, significant hurdles exist within the healthcare system itself. A critical issue is the gap in provider training and knowledge. Studies have revealed that many healthcare providers hold inaccurate beliefs about IUDs, including who is a suitable candidate and the associated risks. Despite a 2012 policy endorsing nurse-led IUD provision to improve access, insertions are still predominantly performed by physicians, creating a bottleneck in the public sector.

Furthermore, deep-seated cultural myths and misinformation contribute to patient hesitancy. Widespread fears about side effects, future fertility, and partner disapproval often deter women from considering IUDs. Public awareness and accurate information are therefore as crucial as the product's physical availability.

An Innovative Partnership for Access

The collaboration behind Avibela is as strategic as the product itself. It pairs Medicines360, a U.S.-based non-profit women’s health innovation organization, with Pharma Dynamics, a South African leader in generic medicines. This partnership structure is central to the mission of making Avibela both accessible and sustainable.

Medicines360 operates on a unique model, focusing on developing essential women's health products and building global access strategies from day one. Their mission is to prioritize women's health over profit, reinvesting revenue to support access in low- and middle-income countries. For Avibela, Medicines360 will provide quality assurance, regulatory oversight, and ensure a stable product supply.

Pharma Dynamics brings its extensive distribution network and deep understanding of the South African market. As a subsidiary of the global pharmaceutical company Lupin Limited, it has the scale and experience to introduce a generic product effectively, navigating both public and private sector channels. This dual-pronged approach aims to disrupt a market long-dominated by high-cost, branded products and make effective contraception a realistic option for more women.

The Road to Widespread Adoption

The launch of Avibela is a promising first step, but its ultimate success will depend on more than just its price tag. For this new option to translate into a tangible public health impact, it must be effectively integrated into the existing healthcare infrastructure.

In the public sector, where contraceptives are provided free of charge, Avibela's inclusion in government formularies will be crucial. However, this must be paired with a concerted investment in provider training. Equipping nurses and midwives at primary healthcare clinics with the skills and confidence to counsel patients and perform IUD insertions is essential to overcome the current service delivery bottleneck.

Simultaneously, public education campaigns will be needed to counter the pervasive myths and build trust in IUDs as a safe and effective option. Addressing women's fears and empowering them with accurate information will be fundamental to driving demand and ensuring informed choice. The availability of a cost-effective product like Avibela provides a powerful new tool, but realizing its full potential will require a coordinated effort from policymakers, healthcare providers, and community advocates to transform the landscape of women's reproductive health in South Africa.